Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 1999

View Archived Issues

CytoTherapeutics reports on new technology for expanding stem/progenitor cell lines

Update on clinical progress of STGI's Anticort for AIDS

Progenics: Q2 1999 highlights

OSI Pharmaceuticals acquires certain Cadus drug discovery programs

GeneTrace and Berlex collaborate on oncology research

Introgen Therapeutics obtains worldwide rights to mda7 gene from Corixa

Fournier returns European rights for tgDCC-E1A to Targeted Genetics

Duramed files for approval of 1.25-mg strength Cenestin tablets

Kinetek obtains patent protection for antidiabetic organovanadium compound

Novel cell adhesion inhibitors in the pipeline at Roche

Structurally unique beta-lactamase inhibitors reported by MethylGene, Wesleyan University

Novel PAF antagonist CPR-3005 claimed in patent literature by Clarion

L-Dopa-induced dyskinesia in primates is reduced significantly by coadministration of (-)-OSU-6162

Takeda scientists synthesize and evaluate GnRH antagonists

New family of ACAT inhibitors described by Merck KGaA

Role of cannabinoid receptors in L-dopa-induced dyskinesia

Preliminary results of SYMPHONY indicate that Xubix is effective in acute coronary syndromes

Purdue Pharma, CoCensys merger agreement announced

Nycomed Amersham files for FDA approval of ultrasound contrast agent

NMDA antagonist NPS-1392 is a candidate for treatment of ischemic stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...